Prevalence and risk factors for colonization of vaginal Candida in reproductive women of Iligan City, Philippines

Paper Details

Research Paper 01/05/2019
Views (424) Download (21)
current_issue_feature_image
publication_file

Prevalence and risk factors for colonization of vaginal Candida in reproductive women of Iligan City, Philippines

Audrey Mae A. Putong, Lady Jane C. Fanuncio, Lucilyn L. Maratas
Int. J. Biosci.14( 5), 343-348, May 2019.
Certificate: IJB 2019 [Generate Certificate]

Abstract

Candida albicans is a opportunistic fungal pathogen of the female genitourinary tract which is known to be a causative agent for vaginal thrush and candidiasis. With a definite lack of information about the prevalence of Candida amongst healthy women of reproductive age in the Philippines, the present study was performed to evaluate prevalence and associated risk factors for the vaginal colonization of C. albicans.  One hundred seventy eligible individuals were recruited to be part of the study whose demographic, lifestyle and medical information were obtained through direct interviews using a semi-structured questionnaire. The self-collected vaginal specimens were obtained and were allowed to grow on Sabouraud Dextrose Agar (SDA) and incubated at ambient room temperature for seven days with a daily assessment of growth. Yeast-like colonies were isolated, purified and identified using phenotypic tests: micromorphology, germ tube test and the use of the chromogenic medium CHROMagar Candida. Ninety-eight samples yielded positive yeast cultures on SDA which is significantly higher that previously published studies. 150 yeast-like isolates were randomly picked and subjected to wet mount examination which showed 23% (35/150) of the isolates formed germ tubes and thus, presumed to be C. albicans. On the other hand, fifty-four isolates yielded green-colored colonies on CHROMagar Candida and were also presumptively identified as C. albicans. Statistical analysis showed no significant association among variables with the isolation of C. albicans. Statistical analysis showed no significant correlation between the isolation of C. albicans and the identified risk factors.

VIEWS 44

Baron EJ, Peterson LR, Finegold SM. 1994. Bailey and Scotts Diagnostic Microbiology, 9th edition, St. Louis: Mosby-Year Book, Inc.

Brandolt TM, Klafke GB, Gonçalves CV, Bitencourt LR, Martinez AM, Mendes JF, Meireles MC, Xavier MO. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Brazilian Journal of Microbiology 48(1), 145-150. http://dx.doi.org/10.1016/j.bjm.2016.09.006.

Cassone A, Sobel JD.  2016. Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis. Infection and Immunity 84, 1255-1261. http://dx.doi.org/10.1123/IAI.01544-15.

Catterall RD. 1971. Influence of gestogenic contraceptive pills on vaginal candidosis. British Journal of Venereal Disease 47, 45-47.

Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. 2018. Global burden of recurrent vulvovaginal candidiasis: a systematic review. The Lancet Infectious Diseases 18(11), e339-e347. https://doi.org/10.1016/S1473-3099(18)30565-6.

Ekuma AE, Ikenyi CL, Moses AE. 2019. Candida Colonization and Genital Hygiene Habits among Women in Uyo, Nigeria. Journal of Research in Basic & Clinical Sciences 1(1).

Guzel AB, Ilkit MT, Akar T, Burgut RIK, Demir SC. 2011. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species. Medical Mycology 49, 16–25. http://dx.doi.org/10.3109/13693786.2010.497972.

Holland J, Young ML, Lee O, ChenS CA . 2003. Vulvovaginal carriage of yeasts other than Candida albicans. Sexually Transmitted Infections 79, 249–250. http://dx.doi.org/10.1136/sti.79.3.249.

Hoppe JE, Frey P. 1999. Evaluation of Six Commercial Tests and the Germ-Tube Test for Presumptive Identification of Candida albicans. European Journal of Clinical Microbiology and Infectious Disease 18, 188–191.

Larone DH. 1995. Medically important fungi: A guide to identification, 3rd Edition, American Society for Microbiology.

Momani MD. 2000. Cost-effectiveness and Efficacy of CHROMagar Candida Medium in Clinical Specimens. Eastern Medical Health Journal 65, 968-975.

Muzny CA, Schwebke JR.  2015. Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections.Clinical Infectious Disease 61(4), 601-6. http://dx.doi.org/10.1093/cid/civ353.

Pfaller MA, Houston A, Coffmann S. 1996. Application of CHROMagar Candida for rapid

screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. Journal of Clinical Microbiology 34(1), 58–61.

Pidwill GR, Rego S, Jenkinson HF, Lamont RJ and Nobbs AH. 2018. Coassociation between Group B Streptococcus and Candida albicans Promotes Interactions with Vaginal Epithelium. Infection and Immunity 86(4), e00669-17. https://doi.org/10/1128/IAI.006699-17.

Rippon JW. 1974. Medical Mycology: The Pathogenic Fungi and the Pathogenic Actinomycetes. W.B. Saunders Co., Philadelphia, 842 p.

Sobel JD. 2007. Vulvovaginal Candidosis. Lancet 369, 1961-1971. https://doi.org/10.1016/S0140-6736(07)60917-9

Van de Wijgert JHHM, Verwij MC, Turner AN, Morrison CS. 2011. Hormonal contraception decreases bacterial vaginosisbut oral contraception may increase candidiasis:implications for HIV transmission. AIDS 27, 2141–2153. http://dx.doi.org/10.1097/QAD.0b013e32836290b6.